Cancer Research UMC Utrecht’s Post

Thrilled to announce the publication of our latest paper titled "Self-supervised Adversarial Adaptation Network for Breast Cancer Detection" in EAAI. This marks my first publication in the field of Artificial intelligence and I couldn't be more proud to be a part of this innovative research team. Thanks to Mahnoosh Torabi and Farhad Pourpanah. 🙏 Check out the paper to learn more about our SOTA results: https://lnkd.in/d22Ua67z #machinelearning #deeplearning #imageprocessing #Breastcancerdetection #Selfsupervisedlearning #Domainadaptation

I’m excited to announce the outcomes of our first independent multi-center clinical study among 28 pathologists in 9 different countries 🌍 in breast cancer diagnostics. It shows that: - 75% of participants experienced improved efficiency when using our product. ⌚ - The algorithm significantly reduced inter-observer variability, resulting in a 32.6% enhancement in consistency among pathologists. 🤝 - 90% of the surveyed pathologists expressing their interest in integrating the algorithm into their daily practice. 🏥 Great work from the Aiosyn and Radboudumc teams and very delighted to have such results from our first clinical study! More is coming… Counting mitoses in histology slides represents a crucial aspect of assessing tumor proliferation rates and plays a pivotal role in breast cancer grading. This process is very tedious and there are many differences among pathologists. Aiosyn Mitosis Breast is designed to assist pathologists with this task, offering laboratories an AI-powered solution that significantly increases efficiency and consistency of results.

July is Sarcoma and Bone Cancer Awareness Month 🎗 #Sarcomas are rare, malignant, and highly heterogeneous (70 subtypes) tumors of bones and soft tissues. Tissue biopsy is currently the gold standard for sarcoma diagnosis, but it has its limitations -   it’s a highly invasive procedure and patients are often diagnosed too late. Liquid biopsy methods could detect early signals of sarcoma and improve the diagnosis and treatment of this cancer.  🩸 A study using Rarecells ISET® Liquid Biopsy platform was the first to detect Circulating tumor cells (CTC) in the blood of patients with sarcoma. In fact, ISET® detected CTCs in all the patients tested . These results open the pathway to studies targeting early detection of sarcoma through liquid biopsy. In a subsequent study using Rarecells ISET® Liquid Biopsy platform, the scientists discovered that the large majority of CTCs in sarcoma patients express a protein called EGFR, a biomarker that may be used to selectively treat sarcoma tumor cells with the  goal of eliminating them . #sarcomaawarenessmonth #CancerAwareness #EarlyDetection #MedicalAdvancements #innovation #ScientificResearch

100% remission rate in a clinical trial for 14 cancer patients. The patients in the trial had tumors with a specific genetic makeup known as mismatch repair-deficient (MMRd) or microsatellite instability (MSI). MMRd tumors develop a defect in their ability to repair certain types of mutations that occur in cells. When those mutations accumulate in the tumor, they stimulate the immune system, which attacks the mutation-ridden cancer cells. All patients received treatment with a checkpoint inhibitor, a type of immunotherapy that blocks the PD-1 protein on T-cells, allowing the immune system to attack the cancer. No patients received any other standard treatments for rectal cancer, such as radiation or surgery. #cancer #oncology #colorectalcancer #immunotherapy

One more promising news about breast cancer screening using AI !! It’s been a few years now and it keeps getting more precise. There are still a few obstacle for large scale implementation, but maybe in a few years it will be common practice ! #AI #healthcare #innovation #cancer #oncology

AI is the future of early breast cancer diagnosis - read more from Brem Foundation to Defeat Breast Cancer's Chief Medical Officer Dr. Rachel Brem in the latest issue Washingtonian Magazine, on this and other important topics, including risks associated with dense breast tissue, the high out of pocket costs for lifesaving screening tests and priority legislation before Congress. #artificialintelligence #ai #earlydetection #cancer Brem Rachel

This graphic shows the composition of cells present within our patient-specific 3D-printed Micro-Tumours.   Carcinotech’s immuno-oncology-focused printed tumours are designed to encapsulate the diversity found within every patient. Our technology provides the solution to existing obstacles encountered in cancer research, by creating a relevant model that incorporates immune cells specific to each patient. Our bioprinted micro-tumours are developed using custom ECM to mimic the native tumour microenvironment.   Carcino3D™ models of patient-specific tumours have been developed for Brain, Lung, Breast, Colorectal and Ovarian cancers with characterised patient populations and mutational status. In addition to these five cancers, our adaptable technology enables us to create models for any solid tumour type. Our ongoing research and development of innovative products ensures customised models for a diverse range of cancers, including rare cancers.   #3dbioprinting #oncology #personalisedmedicine

I found this article mostly relevant to our current research. Find our publication on the machine learning approach to predicting breast cancer here - "https://shorturl.at/buSUV"

Mohammed Qaisi Oral Cancer Institute Innovative Bone Grafts and tissue engineering are transforming the way the jaw can be reconstructed after resection of benign locally aggressive tumors such as ameloblastoma or myxoma. Autogenous bone can be obtained from the anterior ileum, posterior Ileum, or other sites. This can be mixed with bone morphogenic proteins as well as factors from ones own plasma to increase the amount of factors within the bone graft and at the surgical site. Those bone healing factors allow for better integration of the bone and may avoid the need for a fibula flap. if you or a loved one suffer from ameloblastoma, myxoma or other aggressive jaw tumors schedule an appointment with one of our experts at the Oral cancer institute. To find out more, visit our website: https://buff.ly/3t2eCGO #MRONJRecovery #BoneGraftInnovation #OralHealth #AdvancedTreatment #BoneRegeneration #MedicalBreakthrough #PatientCare #OCIExpertise #HealthRevolution #QualityOfLife